The FDA's independent vaccine advisers are recommending Pfizer's vaccine that protects infants from RSV. In a vote Thursday, the panel unanimously said the vaccine efficacy data was sufficient. RSV, a respiratory infection that causes cold-like symptoms, is common in young children. The single-dose shot would be given to expectant mothers late in their pregnancy and trigger the development of antibodies that are passed on to the fetus.